ABSTRACT
Background Severe coronavirus disease 2019 (COVID-19) is characterized, in part, by an excessive inflammatory response. Evidence from animal and human studies suggests that vagus nerve stimulation can lead to reduced levels of various pro-inflammatory cytokines. We conducted a prospective randomized controlled study (SAVIOR-I) to assess the feasibility, efficacy, and safety of non-invasive vagus nerve stimulation (nVNS) for the treatment of respiratory symptoms and inflammatory markers among patients who were hospitalized for COVID-19 (ClinicalTrials.gov identifier: NCT04368156).
Methods Participants were randomly assigned in a 1:1 allocation to receive either the standard of care (SoC) alone or nVNS therapy plus the SoC. The nVNS group received 2 consecutive 2-minute doses of nVNS 3 times daily as prophylaxis. Efficacy and safety were evaluated via the incidence of specific clinical events, inflammatory biomarker levels, and the occurrence of adverse events.
Results Of the 110 participants who were enrolled and randomly assigned, 97 (nVNS, n=47; SoC, n=50) had sufficient available data and comprised the evaluable population. C-reactive protein (CRP) levels decreased from baseline to a significantly greater degree in the nVNS group than in the SoC group at day 5 and overall (ie, all postbaseline data points collected through day 5, combined). Procalcitonin level also showed significantly greater decreases from baseline to day 5 in the nVNS group than in the SoC group. D-dimer levels were decreased from baseline for the nVNS group and increased from baseline for the SoC group at day 5 and overall, although the difference between the treatment groups did not reach statistical significance. No significant treatment differences were seen for clinical respiratory outcomes or any of the other biochemical markers evaluated. No serious nVNS-related adverse events occurred during the study.
Conclusions nVNS therapy led to significant reductions in levels of inflammatory markers, specifically CRP and procalcitonin. Because nVNS has multiple mechanisms of action that may be relevant to COVID-19, additional research into its potential to be used earlier in the course of COVID-19 and possibly mitigate some of the symptoms associated with post-acute COVID-19 syndrome is warranted.
Competing Interest Statement
CT has nothing to disclose. EP has nothing to disclose. MdMG has nothing to disclose. JO has nothing to disclose. MJF has nothing to disclose. IB has nothing to disclose. DLC has served as a consultant and advisory board member for Medtronic, Inc. RV is Director of Research for the National Spine and Pain Centers, a consultant and advisory board member for Medtronic, Inc., and Chief Executive Officer for SGX Medical, LLC. PS is an employee and was cofounder of electroCore, Inc., and receives stock ownership. EJL is an employee of electroCore, Inc., and receives stock ownership.
Clinical Trial
NCT04368156
Funding Statement
electroCore, Inc. (Rockaway, NJ, USA) developed the gammaCore Sapphire device and provided devices at no cost for use in this study. Statistical analysis for the study conducted by North American Science Associates Inc. (Minneapolis, MN, USA) and editorial support from MedLogix Communications, LLC (Itasca, IL, USA) were funded by electroCore, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the Ethics and Clinical Research Committee of INCLIVA, Valencia, Spain [https://www.incliva.es]. INCLIVA is accredited as a Health Research Institute by the Carlos III Health institute, and is affiliated with The Valencia University Clinical Hospital. The study was conducted in accordance with the Declaration of Helsinki and requirements of clinical trials registration (ClinicalTrials.gov identifier NCT04368156). Written informed consent from patients was required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Study funding electroCore, Inc. (Rockaway, NJ, USA) developed the gammaCore Sapphire™ device and provided devices at no cost for use in this study. Statistical analysis for the study conducted by North American Science Associates Inc. (Minneapolis, MN, USA) and editorial support from MedLogix Communications, LLC (Itasca, IL, USA) were funded by electroCore, Inc.
Author disclosures CT has nothing to disclose.
EP has nothing to disclose.
MdMG has nothing to disclose.
JO has nothing to disclose.
MJF has nothing to disclose.
IB has nothing to disclose.
DLC has served as a consultant and advisory board member for Medtronic, Inc.
RV is Director of Research for the National Spine and Pain Centers, a consultant and advisory board member for Medtronic, Inc., and Chief Executive Officer for SGX Medical, LLC.
PS is an employee and was cofounder of electroCore, Inc., and receives stock ownership.
EJL is an employee of electroCore, Inc., and receives stock ownership.
Data availability statement: Data from the SAVIOR I study will be publicly available at ClinicalTrials.gov with the identifier NCT04368156. Individual participant data will not be shared.
Data Availability
Data from the SAVIOR I study will be publicly available at ClinicalTrials.gov with the identifier NCT04368156. Individual participant data will not be shared.
